Loading organizations...
§ Private Profile · San Diego, CA, USA
Molecular diagnostics company providing IDgenetix pharmacogenomics (PGx) testing for personalized medication decisions in mental health.
Based in San Diego, California, AltheaDx is a commercial-stage molecular diagnostics company that provides pharmacogenomics testing services to help healthcare providers personalize medication decisions. The organization operates a CAP-accredited, CLIA-certified laboratory approved by the New York State Department of Health, utilizing its proprietary IDgenetix algorithm to analyze genetic data for clinical conditions including neuropsychiatric disorders, cardiovascular disease, and pain management. Operating with approximately 50 to 100 employees, the enterprise has tested over 100,000 patients and secures reimbursement through major commercial health insurance providers and Medicare. In April 2022, the molecular diagnostic firm was officially acquired by Castle Biosciences for an initial $65 million, with the definitive agreement including up to $75 million in additional milestone payments. AltheaDx was originally founded in 2004 as a spin-off from Althea Technologies by co-founders Magda Marquet and François Ferré.
AltheaDx has raised $63.0M across 3 funding rounds.
AltheaDx has raised $63.0M in total across 3 funding rounds.
AltheaDx has raised $63.0M in total across 3 funding rounds.
AltheaDx's investors include Li Wei, Ally Bridge Group, François Ferré, WuXi AppTec, Telegraph Hill Partners.
AltheaDx has raised $63.0M across 3 funding rounds. Most recently, it raised $27.0M Series D in April 2017.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 25, 2017 | $27M Series D | — | — | Announced |
| Dec 14, 2015 | $30M Series C | LI WEI | Ally Bridge Group, François Ferré, WuXi AppTec | Announced |
| Apr 13, 2010 | $6M Series A | Telegraph Hill Partners | — | Announced |